Skip to content

Primary pulmonary hyalinizing clear cell carcinoma with KRAS G12A mutation

Primary pulmonary hyalinizing clear cell carcinoma with KRAS G12A mutation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125415
Enrollment
Unknown
Registered
2026-05-26
Start date
2026-05-26
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary clear cell lung cancer

Interventions

a primary pulmonary HCCC case harboring a KRAS G12A mutation:NA

Sponsors

Beidahuang Industry Group General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
38 Years to 44 Years

Inclusion criteria

Inclusion criteria: 1.Volunteers voluntarily participated in the study and signed the informed consent form. 2.This is a case of primary pulmonary hyaline-like hyaline change carcinoma that was admitted to our hospital and was diagnosed through pathological examination, immunohistochemistry, and molecular testing. This case has complete clinical, imaging, pathological, molecular testing, and follow-up data, which can be used to analyze its clinical and pathological characteristics, KRAS G12A mutation status, and treatment response. 3.Male or female, 18 years old <= age <= 65 years old. 4. Meets the diagnostic criteria for primary clear cell carcinoma.

Exclusion criteria

Exclusion criteria: 1.Suffering from a second primary tumor disease. 2.Pregnancy or lactation. 3.Treat with other experimental drugs or other intervention measures within a specific time frame.

Design outcomes

Primary

MeasureTime frame
The prognosis of patients with primary pulmonary HCCC carrying KRASG12A mutation.;

Countries

China

Contacts

Public ContactZhang Xin

Beidahuang Industry Group General Hospital

564540863@qq.com+86 451 5519 7696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026